MaxCyte Earnings Call Transcripts
Fiscal Year 2025
-
2025 saw revenue decline 15% year-over-year amid SPL program exits and inventory headwinds, but new product launches, cost restructuring, and a strong balance sheet position the company for growth. 2026 guidance anticipates $30–32 million in revenue, with a back-half weighted recovery and material contributions from SeQure Dx and SPL milestones.
-
Recent restructuring and SecureDx acquisition sharpened focus on early-stage customer engagement and safety in cell and gene therapy. Despite industry rationalization, strong margins and new product launches are expected to drive growth, with a rebound anticipated in the second half of next year.
-
Q3 2025 revenue declined year-over-year but met expectations, with cost-saving restructuring underway and a strong SPL pipeline. SecureDX integration and new product launches are expected to drive growth in 2026, while the company maintains a robust cash position and disciplined M&A focus.
-
Q2 2025 revenue declined 18% year-over-year, prompting a reduction in 2025 core revenue guidance due to customer program rationalizations and capital equipment hesitancy. Despite headwinds, instrument sales grew 22% and new SPLs were signed, with growth expected to resume in 2026.
-
Q1 2025 revenue was $10.4M, down 8% year-over-year, with core revenue flat and SPL revenue at $2.1M. Guidance for 2025 is reaffirmed, integration of SecureDX is progressing well, and the company remains well-capitalized with $174.7M in cash and no debt.
-
The ExPERT platform's high-efficiency, scalable electroporation is driving growth in cell and gene therapy, especially as the industry shifts toward allogeneic and autoimmune applications. Strategic acquisitions like SeQure Dx and robust SPL economics position the company for continued expansion and profitability.
Fiscal Year 2024
-
Core revenue grew 9% in 2024, driven by strong PA sales and SPL portfolio expansion, despite a 6% decline in total revenue due to prior year milestones. The SeQure Dx acquisition broadens service offerings, and 2025 guidance projects 8%-15% core revenue growth with continued market caution.
-
Leadership emphasized renewed focus on cell and gene therapy, operational excellence, and expanding product offerings. The electroporation platform is validated by commercial approvals and strong SPL growth, with robust financials and a positive long-term outlook.
-
Cell and gene therapy markets are shifting toward non-viral, ex vivo approaches, driving strong revenue growth and increased SPL activity. Financial performance improved in 2024, with optimism for continued momentum and more predictable SPL-driven revenue as programs mature.
-
Q3 2024 revenue grew 2% to $8.2M, with core revenue up 23% and strong cell therapy performance. Six new SPLs were signed, a record, and 2024 core revenue growth guidance was raised to at least 5%. Gross margin was impacted by a one-time write-off, but cash remains strong.
-
Q2 2024 revenue rose 15% year-over-year to $10.4M, driven by strong SPL program-related revenue and five new SPLs signed. Core revenue declined 9% year-over-year, but gross margin improved to 86%. Guidance for 2024 remains unchanged, with a focus on cell therapy growth and disciplined spending.
-
Cell and gene therapy is rapidly advancing, with non-viral ex vivo engineering enabling new curative treatments and expanding into diverse indications. The platform's robust technology and business model support a growing pipeline, high margins, and strong financials, as seen with recent product approvals and new licenses.